Coagulation pathway assembly on activated platelets

Coagulation pathway assembly on activated platelets is a critical physiological process where the platelet membrane acts as a catalytic scaffold for the blood coagulation cascade (StatPearls, PMID: 25048328). Upon activation, platelets undergo a membrane rearrangement that exposes negatively charged phosphatidylserine, which facilitates the binding of vitamin K-dependent clotting factors via calcium ions (PubMed, PMID: 15507607). This surface allows for the assembly of the tenase complex (Factors IXa and VIIIa) and the prothrombinase complex (Factors Xa and Va), leading to a massive burst of thrombin generation. This localized assembly ensures that clot formation is restricted to the site of vascular injury, preventing systemic coagulation. However, pathological activation of this process is a primary driver of arterial and venous thrombosis, contributing to conditions like myocardial infarction and deep vein thrombosis (Journal of Thrombosis and Haemostasis, 2011). Pharmacological strategies to manage these conditions involve targeting the enzymes within these complexes, such as Factor Xa or Thrombin, or reducing platelet activation itself (NIH, StatPearls). Balancing the inhibition of this assembly to prevent thrombosis while maintaining adequate hemostasis remains a significant therapeutic challenge.

Other names

Platelet-dependent coagulationProcoagulant platelet activityTenase and prothrombinase complex assemblyPlatelet-based thrombin generation

Direct or indirect inhibition of the enzymatic components of the tenase and prothrombinase complexes, specifically Factor Xa and Thrombin, to prevent the amplification of the coagulation cascade on the platelet surface.